Friday - January 23, 2026

Category Archives: Pharmaceuticals & Biotech

22q11.2 Deletion Syndrome Market Set for Growth Through 2034, with the US Leading Demand and 185+ Associated Conditions Shaping Unmet Clinical Needs | DelveInsight

22q11.2 Deletion Syndrome Market 22q11.2 Deletion Syndrome Companies are Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others. The United States represents the largest 22q11.2 deletion syndrome market compared with EU4, the United Kingdom, and Japan. The … Continue reading →

Huntington’s Disease Market Poised for Transformation Through Gene Therapies and RNA-Targeted Innovations, with the US Accounting for Over 70% of Global Opportunity | DelveInsight Forecast 2034

Huntington’s Disease Market Huntington’s Disease Clinical Trial Companies are Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, … Continue reading →

Psoriatic Arthritis Market Outlook 2034: 7MM Epidemiology, 30+ Key Companies, and Next-Gen IL-17 & TYK2 Therapies Uncovered by DelveInsight

Psoriatic Arthritis Market Psoriatic Arthritis companies working in the market are UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, Teva Pharma, Boehringer Ingelheim, AbbVie, Roche, Ampio Pharmaceuticals, Antares Pharma, Currax Pharmaceuticals, GlaxoSmithKline, … Continue reading →

Persistent Corneal Epithelial Defects Treatment Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects pipeline landscape. It covers the Persistent Corneal Epithelial Defects pipeline drug profiles, including clinical and nonclinical … Continue reading →

Autistic Disorder Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Autistic Disorder Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Autistic Disorder pipeline landscape. It covers the Autistic Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Hereditary Angioedema Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Hereditary Angioedema Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight

NK Cell Therapy Market Major developers active in the NK cell therapy space include MiNK Therapeutics, Indapta Therapeutics, ImmunityBio, Inc., Allife Medical Science and Technology, Biohaven Pharmaceuticals, Acepodia, Bright Path Biotherapeutics, Amgen, Innate Pharma, Nektar Therapeutics, SMT bio Co., Ltd., … Continue reading →